NL-OMON48315已完成不适用
ABSORB-2:An exploratie study determining the oral antibiotic drug absorption in patients with short bowel syndrome. - ABSORB2
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Patients with current use of long-term home parenteral nutrition (at least 3
- •consecutive months) and clinically stable
- •- Diagnosed with SBS (total small bowel length 200cm or less after Treitz
- •ligamentum)
- •- Age 18 years of older
- •- Signed Informed Consent
- •- Patient is fully able to understand the nature of the proposed intervention.
排除标准
- •- Active vomiting, worsening or new diarrhea
- •- Contra-indications (for example allergies or interfering co-medication) for
- •any of the study treatments
- •- Impaired renal function (creatinin clearance <30ml/min/1,73m2)
- •- Pregnancy
- •- Morbid obesity (BMI >35)
- •- Any current or prior medical condition that may interfere with the conduct of
- •the study or the evaluation of its results in the opinion of the investigator
研究者
相似试验
进行中（未招募）
1 期
Research for bowel absorption of antibiotic tablets in patients with short bowel syndromeshort bowel syndrome, home parenteral nutritionEUCTR2019-002587-28-NLRadboudumc16
招募中
Unknown
Observational Study on the Development of an Oral Condition Assessment SystemPeriodontal DiseaseJPRN-UMIN000053610Sunstar Inc.400
进行中（未招募）
1 期
Study to determine whether adding MLN9708 to the combination of cyclophosphamide and dexamethasone improves the response to therapy in patients who have been newly diagnosed with multiple myeloma and have not received previous anti-myeloma treatmentewly diagnosed multiple myelomaMedDRA version: 14.1Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2013-003113-17-GRMillennium Pharmaceuticals, Inc.70
进行中（未招募）
1 期
Study to determine whether adding MLN9708 to the combination of cyclophosphamide and dexamethasone improves the response to therapy in patients who have been newly diagnosed with multiple myeloma and have not received previous anti-myeloma treatment, and in patients with multiple myeloma whose disease is no longer responding or has not responded to previous treatmentEUCTR2013-003113-17-SEMillennium Pharmaceuticals, Inc.148
进行中（未招募）
1 期
Study to determine whether adding MLN9708 to the combination ofcyclophosphamide and dexamethasone improves the response to therapyin patients who have been newly diagnosed with multiple myeloma andhave not received previous anti-myeloma treatment, and in patients withmultiple myeloma whose disease is no longer responding or has notresponded to previous treatmentewly diagnosed multiple myelom and relapsed and/or refractorymultiple myelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000054086EUCTR2013-003113-17-PLMillennium Pharmaceuticals, Inc.148